問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

Division of General Surgery

National Taiwan University Hospital

更新時間：2023-09-19

徐鴻智Hsu, Hung-Chih
  • Principal Investigator
  • Clinical Trial Experience (year) 24 years 3 個月

Recruiting Trial

75Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

徐鴻智

List

145Cases

2017-01-17 - 2020-09-30

Phase III

Completed
A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE 3 STUDY OF NIVOLUMAB PLUS IPILIMUMAB VERSUS OXALIPLATIN PLUS FLUOROPYRIMIDINE IN SUBJECTS WITH PREVIOUSLY UNTREATED ADVANCED OR METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION CANCER

  • Condition/Disease

    Gastric Cancer,Gastroesophageal Junction Cancer

  • Test Drug

    Nivolumab/Ipilimumab/Oxaliplatin/Fluorouracil/Leucovorin/Capecitabine

Participate Sites
2Sites

Terminated1Sites

Study ended1Sites

陳仁熙
Linkou Chang Gung Medical Foundation

洪逸平
Taipei Veterans General Hospital

Division of Hematology & Oncology

2017-01-15 - 2020-01-31

Phase I

Completed
Phase Ib, open-label, multi-center study to characterize the safety, tolerability and pharmacodynamics (PD) of PDR001 in combination with CJM112, EGF816, IlarisR (canakinumab) or MekinistR (trametinib)

  • Condition/Disease

    Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma

  • Test Drug

    PDR001、CJM112、ACZ885/Ilaris® 、EGF816、TMT212/Mekinist®

Participate Sites
2Sites

Terminated1Sites

Study ended1Sites

侯明模
Linkou Chang Gung Medical Foundation

2025-10-01 - 2028-12-31

Phase I/II

Active
An Open-label, Multicenter, Phase 1/2 Study Exploring the Safety and Efficacy of ABT-301 in Combination With Tislelizumab and Bevacizumab in Participants With Proficient Mismatch Repair (pMMR)/Non-Microsatellite Instability-High (Non-MSI-H) Locally Advanced or Metastatic Colorectal Cancer (mCRC)

  • Condition/Disease

    Colorectal Cancer (Diagnosis)

  • Test Drug

    膠囊劑 靜脈輸注液 靜脈輸注液 膠囊劑

Participate Sites
7Sites

Recruiting7Sites

2025-02-20 - 2027-10-29

Phase II

Not yet recruiting
Innovative Trial Interventional Therapies and Combinations for Colorectal Cancer: Key Program for Participants

  • Condition/Disease

    Colorectal cancer

  • Test Drug

    MEDI5752

Participate Sites
4Sites

Recruiting4Sites

2025-03-01 - 2030-02-01

Phase III

Active
A multicenter, randomized, open-label, phase III trial (DESTINY-Gastric05) evaluating trastuzumab Deruxtecan (Enhertu®) with chemotherapy (with or without pembrolizumab) versus chemotherapy with or without trastuzumab as first-line treatment for patients with unresectable, locally advanced, or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) cancer.

  • Condition/Disease

    HER2-positive gastric cancer or gastroesophageal junction cancer

  • Test Drug

    Trastuzumab Deruxtecan (T-DXd)

Participate Sites
5Sites

Recruiting5Sites

2025-11-01 - 2031-12-31

Phase III

Active
A Phase III, Multicentre, Randomised Controlled Study of Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in First-Line Claudin18.2-Positive, HER2-Negative, Advanced/Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (CLARITY-Gastric 02)

  • Condition/Disease

    Gastroesophageal Junction Adenocarcinoma

  • Test Drug

    凍晶乾燥注射劑 注射劑

Participate Sites
8Sites

Not yet recruiting1Sites

2021-04-01 - 2033-02-28

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2012-11-30 - 2017-06-30

Phase IV

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2021-10-18 - 2026-11-22

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting5Sites

Recruiting3Sites

2026-01-15 - 2031-03-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting6Sites

1 2 3 4 5 15
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB